ClinicalTrials.gg
RecruitingNCT07586735Updated Jul 6, 2026

A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA

An observational study in Severe Aplastic Anemia, Aplastic Anaemia and Hematopoietic Cell Transplant, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Peking University People's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
64
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Anemia, Aplastic by Peking University People's Hospital — 9 open to participants now, 9 under way, 1 of them phase 3. Anemia, Aplastic · Peking University People's Hospital.

Started
2026
with 4 others
Observational
3 of 10
3 open now
Registered
6th of 10
by date

Among the 10 studies in Anemia, Aplastic by Peking University People's Hospital, this one is one of 5 that started in 2026, is one of 3 observational ones, and was the 6th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

9 of the 10 studies in Anemia, Aplastic by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 40 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Anemia, Aplastic by Peking University People's Hospital, or all of them as a file.
02

Study summary

The goal of this prospective, multicenter, single arm observational study is to evaluate the efficacy and safety of the BFCA regimen in ≥ 40 years old SAA patients undergoing haplo-HSCT.

03

Conditions studied

  • Severe Aplastic Anemia
  • Aplastic Anaemia
  • Hematopoietic Cell Transplant

Browse trials for

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 40-60 years old who are diagnosed with severe aplastic anemia according to NCCN guidelines and who will receive haploidentical hematopoietic stem cell transplantation at the centers will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe aplastic anemia;
  • Aged 40-60 years old;
  • Weight 45Kg-100Kg;
  • (ECOG) score ≤3;
  • No major organ injury ( >45%; \< 2 times the value; and ALT \< 3 times the upper limit of normal value; serum creatinine \< 2 times the upper limit of normal value);
  • No severe infection;
  • Subjects voluntarily participated in this clinical trial and signed the .

Exclusion criteria

Exclusion Criteria:

  • With other hematologic diseases;
  • Expected survival of less than 1 month;
  • Previous or allogeneic hematopoietic stem cell transplantation;
  • Pregnant patients;
  • Patients with severe mental or neurological disorders that would affect the ability to provide and/or to report or observe adverse events;
  • Other conditions that the investigator determines to be inappropriate for enrollment.
  • Current or recent (\<4 weeks prior to screening) clinically serious viral, bacterial, fungal, or parasitic infection
  • A history of symptomatic herpes zoster infection within 12 weeks prior to screening
  • Active or chronic viral infection from virus (HBV), virus (HCV), or (HIV)
  • Have evidence of active tuberculosis (TB), or have previously had evidence of active TB and did not receive appropriate and documented treatment, or have had household contact with a person with active TB and did not receive appropriate and documented prophylaxis for TB
  • Exposure to a within 12 weeks prior to enrollment or expected to receive a live vaccine during the study
  • thrombotic event within 24 weeks of screening or are on anticoagulants and in the opinion of the investigator are not well controlled
  • Myocardial infarction (MI), unstable ischemic heart disease, stroke, or Stage IV heart failure
  • A history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking product or interfere with the interpretation of data
  • Any of the following specific abnormalities on screening laboratory tests:

    1. or AST >2 x , or total ≥1.5 x ULN
    2. \<9 g/dL, or total white blood cell (WBC) count \<2,500/µL, or neutropenia ( \<1,200/µL), or lymphopenia (lymphocyte count \<750/µL)
    3. \<50 mL/min/1.73 m2
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
64 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Peking unviversity Peoples' Hospital

    Drug: BFCA conditiong regimen

  • The First Affiliated Hospital of Soochow University

    Drug: BFCA conditiong regimen

  • Guangzhou First People's Hospital,

    Drug: BFCA conditiong regimen

  • The First Affiliated Hospital of USTC

    Drug: BFCA conditiong regimen

Interventions

  • DrugBFCA conditiong regimen

    busulfan 0.8 mg/kg/6h (days -8 to -7), fludarabine 30mg/m2/day (days -6 to -2), cyclophosphamide 25 mg/kg/day (days -5 to -2) and antithymocyte globulin(ATG) 2.5 mg/kg/day (days -5 to -2).

06

What researchers measure

Primary outcomes

  1. Faliure free survival (FFS)

    survival with a response to therapy after HSCT. Death, graft faliue and relapse were considered as treatment failure.

    Time frame: From enrollment to 2 years post-HSCT

Secondary outcomes

  1. The probability of Overall survival

    Overall survival was defined as the time from transplantation to death from any cause or to the last follow-up

    Time frame: From enrollment to 2 years post-HSCT

  2. Myeloid and platelet engraftment

    Myeloid and platelet engraftment were defined as international criteria.

    Time frame: 100 days post HSCT

  3. The incidence of mixed chimerism

    The mixed chimerism was defined as the presence of 5%-95% donor haematopoietic cells.

    Time frame: 1 year post HSCT

  4. The incidence of graft versus host disease(GVHD)

    The severity of acute and chronic GVHD was evaluated according to standard criteria.

    Time frame: 100 days post HSCT for aGvHD and 2 years post HSCT for cGvHD

  5. Regimen related toxicity

    The regimen related toxicity (RTT) was measured according to the Seattle Toxicity Criteria (Bearman et al, 1988).

    Time frame: 100 days post HSCT

  6. The incidence of Cytomegalovirus(CMV) and Epstein-Barr virus(EBV) reactivation

    The incidence of CMV and EBV reactivation was defined as CMV and EBV viremia.

    Time frame: 180 days post HSCT

  7. The incidence of Transplantation related mortality

    Transplantation related mortality was defined as death without disease progression.

    Time frame: 2 years post HSCT

07

Study locations

1 of 1 sites recruiting
  • Peking Universtiy Peoples' Hospital
    Beijing, Beijing Municipality 100044, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 14, 2026
StartEst.
Jun 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 30, 2029
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07586735
Responsible party
Xiao-Jun Huang (Professor, Peking University People's Hospital) — Principal investigator
First posted
May 14, 2026
Start date
Jun 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Jul 6, 2026

Study contacts

Tingting Han
Contact
htt1984.love@163.com
8601088326666

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion